Results 41 to 50 of about 8,864 (209)

Understanding the Radiobiological Mechanisms Induced by 177Lu-DOTATATE in Comparison to External Beam Radiation Therapy

, 2022
Radionuclide Therapy (RNT) with 177Lu-DOTATATE targeting somatostatin receptors (SSTRs) in neuroendocrine tumours (NET) has been successfully used in routine clinical practice, mainly leading to stable disease.
Patrick Flamen, Delbart, Wendy, Ghanem, Ghanem E., Ghanem, Ghanem Elias, Penninckx, Sébastien, Zéna Wimana, Flamen, Patrick, Gwennaëlle Marin, Derrien, Jonathan, Jirair Karabet, Sébastien Penninckx, Wimana, Zéna, Jonathan Derrien, Wendy Delbart, Ghanem E. Ghanem, Karabet, Jirair, Marin, Gwennaëlle   +16 more
core   +1 more source

Behandling av Nevroendokrine Tumorer med 177Lu-DOTATATE - Fra Pasientens Perspektiv [PDF]

, 2021
I 2020 ble det på bakgrunn av en internasjonal beslutning innført peptidreseptor-nuklideterapi med 177Lu-DOTATATE ved fire norske sykehus, som et behandlingsalternativ for pasienter med nevroendokrine tumorer (NETs).
Eiriksson, Frida
core   +1 more source

Efficacy and safety of 177Lu-DOTATATE targeted therapy in advanced/metastatic pulmonary neuroendocrine tumors: A systematic review and meta-analysis

Frontiers in Oncology, 2022
ObjectiveTo perform a meta-analysis of the efficacy and safety about 177Lu-DOTATATE therapy for advanced/metastatic pNETs based on the current clinical evidence.MethodsThis systematic review follows the PRISMA guideline.
Jiao Ma, Xin Hu, Lanying Li, Zijuan Rao, Chunyin Zhang, Chunyin Zhang, Chunyin Zhang   +6 more
doaj   +1 more source

Uncovering G Protein‐Coupled Receptors: Novel Targets and Biomarkers for Predicting Glioma Prognosis

Annals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Low‐grade gliomas (LGG) exhibit significant heterogeneity and recurrence risk. G protein‐coupled receptors (GPCR) contribute to glioma malignant progression, but their prognostic value remains unclear. This work attempts to formulate a GPCR‐based outcome‐predicting model for LGG. Methods Based on TCGA LGG data, the enrichment scores
Jun Yang, Dongxu Zhang, Dongyuan Liu, Da Lin, Hao Wang   +4 more
wiley   +1 more source

[161Tb]Tb-DOTATATE as a potential treatment option for neuroblastoma

EJNMMI Research
Background Neuroblastoma is an aggressive paediatric malignancy with poor outcomes in high-risk patients despite multimodal therapy. [177Lu]Lu-DOTATATE, targeting somatostatin receptor 2 (SSTR2), is under clinical investigation for neuroblastoma. Terbium-
Saloni Chopra, Tianqi Xu, Hanna Berglund, Amanda Gustafsson, Marika Nestor   +4 more
doaj   +1 more source

Toward Personalized Theranostics: A Modular PET Platform for Antibody‐Based Imaging and Therapy

Advanced Science, EarlyView.
This modular, site‐specific antibody platform enables customizable conjugates for PET imaging and therapy. Interchangeable payloads – including radiometals, cytotoxics, and fluorophores – support adaptable, multimodal applications with limited off‐target effects. In vivo, the DFO/DOTAGA bischelate immunoconjugate provided clear tumor delineation in PET/
Delphine Vivier, Megane Grah Kple, Julen Ariztia, Marion Leroux, Mathieu Moreau, Michael Claron, Maxime Cheveau, Adam Laouafa, Agnieszka Kownacka, Camille Petitot, John Simonet, Alexandre M. M. Dias, Sophie Poty, Charles Truillet, Bertrand Collin, Alexandra Oudot, Franck Denat   +16 more
wiley   +1 more source

Somatostatin Receptor Theranostics for Refractory Meningiomas

Current Oncology, 2022
Somatostatin receptor (SSTR)-targeted peptide receptor radionuclide therapy (PRRT) represents a promising approach for treatment-refractory meningiomas progressing after surgery and radiotherapy.
Betty Salgues, Thomas Graillon, Tatiana Horowitz, Olivier Chinot, Laetitia Padovani, David Taïeb, Eric Guedj   +6 more
doaj   +1 more source

Dual‐Target Nectin‐4/FAP Heterobivalent Probe 68Ga/177Lu‐FZ‐NF‐1 for Triple‐Negative Breast Cancer: Preclinical Theranostic Evaluation and First‐in‐Human Translation

Advanced Science, EarlyView.
A novel hetero‐bivalent agent, 68Ga/177Lu‐FZ‐NF‐1, concurrently targets Nectin‐4 and FAP in triple‐negative breast cancer. It yields significant preclinical tumor regression and clinically identifies additional metastatic lesions missed by 18F‐FDG PET, demonstrating promising theranostic potential for personalized management.
Ye Li, Li Sun, Xiaoyu Pan, Shuyi Lin, Dongliang Wang, Jianping Zhang, Fengshuang Qiu, Bin Zhu, Lingzhou Zhao, Fengsheng Zhang, Liyan Bai, Bingxin Gu, Xiaoping Xu, Shaoli Song   +13 more
wiley   +1 more source

Evaluation of carrier added (CA) and no carrier added (NCA) 177Lu radionuclide roles in radiolabeling of peptide groups [PDF]

مجله علوم و فنون هسته‌ای, 2020
The peptides radiolabeled with 177Lu are including a wide range of promising radiopharmaceuticals. The NCA form of 177Lu provides a high specific activity that is required in targeted receptor therapy in order to avoid saturation of the targeted ...
S. Vosoughi, N. Salek, M. Ghannadi Maragheh   +2 more
doaj   +1 more source

Epigenetic Dysregulation of Somatostatin Receptors (SSTR) 1–5 and Therapeutic Implications in Neuroendocrine and Non‐Neuroendocrine Malignancies

International Journal of Cancer, EarlyView.
ABSTRACT Somatostatin receptors (SSTR) mediate the antiproliferative, antisecretory, and proapoptotic effects of somatostatin and its synthetic analogs. Their surface expression on neuroendocrine tumor (NET) cells is required for somatostatin analog therapy and radiopharmaceutical therapy (RPT).
Neeraj Kumari, Pablo Hoffmann, Laura Reichl, Maximilian Schmutz, Nina Fischer, Thi Tuong Vi Dang, Fulvia Ferrazzi, Pascal Johann, Michaela Kuhlen, Constantin Lapa, Rainer Claus   +10 more
wiley   +1 more source